Next Article in Journal
The p53 Pathway in Glioblastoma
Next Article in Special Issue
Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
Previous Article in Journal / Special Issue
Epigenetic Crosstalk between the Tumor Microenvironment and Ovarian Cancer Cells: A Therapeutic Road Less Traveled
Article Menu

Export Article

Open AccessReview
Cancers 2018, 10(9), 296; https://doi.org/10.3390/cancers10090296

Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Kansas Medical Center, Kansas, KS 66160, USA
*
Author to whom correspondence should be addressed.
Received: 5 June 2018 / Revised: 14 August 2018 / Accepted: 16 August 2018 / Published: 1 September 2018
(This article belongs to the Special Issue The Tumor Microenvironment of High Grade Serous Ovarian Cancer)
Full-Text   |   PDF [189 KB, uploaded 1 September 2018]

Abstract

Heated intraperitoneal chemotherapy (HIPEC) has several potential benefits. Higher doses of chemotherapy can be used with HIPEC because the plasma-peritoneal barrier results in little absorption into the blood stream. HIPEC offers higher peritoneal penetration in comparison to an intravenous (IV) regimen and does not have the traditional normothermic intraperitoneal (IP) regimen limitation of post-operative adhesions. Hyperthermia itself has cytotoxic effects and can potentiate antineoplastic effects of chemotherapy in part by increasing the depth of tumor penetration by up to 3 mm. For the treatment of ovarian cancer, HIPEC has been evaluated in the recurrent setting with secondary cytoreduction. Recent studies, including a prospective trial, have evaluated its role in primary management of ovarian cancer. This review summarizes previous and ongoing studies regarding the use of HIPEC in the management of ovarian cancer. View Full-Text
Keywords: ovarian cancer; heated intraperitoneal chemotherapy (HIPEC); intraperitoneal chemotherapy (IP); cytoreductive surgery; secondary cytoreduction; interval cytoreduction ovarian cancer; heated intraperitoneal chemotherapy (HIPEC); intraperitoneal chemotherapy (IP); cytoreductive surgery; secondary cytoreduction; interval cytoreduction
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Jewell, A.; McMahon, M.; Khabele, D. Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer. Cancers 2018, 10, 296.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top